96 related articles for article (PubMed ID: 30124372)
21. Pattern of chronic myeloid leukemia in the imatinib era in a Sub-Saharan African setting.
Faye BF; Dieng N; Seck M; Gadji M; Gueye YB; Sy D; Toure SA; Sall A; Toure AO; Dieye TN; Diop S
Ann Hematol; 2016 Oct; 95(10):1603-10. PubMed ID: 27370991
[TBL] [Abstract][Full Text] [Related]
22. U.S. Food and Drug Administration Drug Approval Summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval.
Cohen MH; Johnson JR; Pazdur R
Clin Cancer Res; 2005 Jan; 11(1):12-9. PubMed ID: 15671523
[TBL] [Abstract][Full Text] [Related]
23. Monitoring Chronic Myeloid Leukemia in the Real World: Gaps and Opportunities.
Goldberg SL
Clin Lymphoma Myeloma Leuk; 2015 Dec; 15(12):711-4. PubMed ID: 26433907
[TBL] [Abstract][Full Text] [Related]
24. Elevated Cardiovascular Disease Risk in Patients With Chronic Myelogenous Leukemia Seen in Community-based Oncology Practices in the United States.
Coutinho AD; Makenbaeva D; Farrelly E; Landsman-Blumberg PB; Lenihan D
Clin Lymphoma Myeloma Leuk; 2017 Oct; 17(10):676-683. PubMed ID: 28729178
[TBL] [Abstract][Full Text] [Related]
25. The impact of medical insurance coverage and molecular monitoring frequency on outcomes in chronic myeloid leukemia: real-world evidence in China.
Sheng G; Chen S; Zhang R; Miao M; Wu D; Tan SC; Liu C; Xiong T
J Med Econ; 2017 Apr; 20(4):382-387. PubMed ID: 27937141
[TBL] [Abstract][Full Text] [Related]
26. International patterns of childhood chronic myeloid leukemia: comparisons between the United States and resource-restricted nations.
Sadak KT; Fultz K; Mendizabal A; Reaman G; Garcia-Gonzalez P; Levine PH
Pediatr Blood Cancer; 2014 Oct; 61(10):1774-8. PubMed ID: 24976310
[TBL] [Abstract][Full Text] [Related]
27. Dasatinib: from treatment of imatinib-resistant or -intolerant patients with chronic myeloid leukemia to treatment of patients with newly diagnosed chronic phase chronic myeloid leukemia.
Abbott BL
Clin Ther; 2012 Feb; 34(2):272-81. PubMed ID: 22285209
[TBL] [Abstract][Full Text] [Related]
28. Survival for patients with chronic leukemias in the US and Britain: Age-related disparities and changes in the early 21st century.
Pulte D; Redaniel MT; Bird J; Jeffreys M
Eur J Haematol; 2015 Jun; 94(6):540-5. PubMed ID: 25315799
[TBL] [Abstract][Full Text] [Related]
29. Factors Associated With Tyrosine Kinase Inhibitor Initiation and Adherence Among Medicare Beneficiaries With Chronic Myeloid Leukemia.
Winn AN; Keating NL; Dusetzina SB
J Clin Oncol; 2016 Dec; 34(36):4323-4328. PubMed ID: 27998234
[TBL] [Abstract][Full Text] [Related]
30. Health Care Resource Use, Costs, and Diagnosis Patterns in Patients With Schizophrenia and Bipolar Disorder: Real-world Evidence From US Claims Databases.
Broder MS; Greene M; Chang E; Hartry A; Touya M; Munday J; Yan T
Clin Ther; 2018 Oct; 40(10):1670-1682. PubMed ID: 30193748
[TBL] [Abstract][Full Text] [Related]
31. The impact of comorbid disease history on all-cause and cancer-specific mortality in myeloid leukemia and myeloma - a Swedish population-based study.
Mohammadi M; Cao Y; Glimelius I; Bottai M; Eloranta S; Smedby KE
BMC Cancer; 2015 Nov; 15():850. PubMed ID: 26537111
[TBL] [Abstract][Full Text] [Related]
32. [Early monitoring of BCR-ABL transcript levels and cytogenetic in assessing the prognosis of chronic myeloid leukemia].
Huang Q; Zhang XY; Li Y; Wang XM
Zhonghua Yi Xue Za Zhi; 2013 Oct; 93(38):3049-53. PubMed ID: 24417926
[TBL] [Abstract][Full Text] [Related]
33. Adherence to quality indicators in chronic myeloid leukemia care: results from a population-based study in The Netherlands.
Ector GICG; Geelen IGP; Dinmohamed AG; Hoogendoorn M; Westerweel PE; Hermens RPMG; Blijlevens NMA
Leuk Lymphoma; 2023 Feb; 64(2):424-432. PubMed ID: 36369821
[TBL] [Abstract][Full Text] [Related]
34. Management of chronic myeloid leukemia in France: a multicentered cross-sectional study on 538 patients.
Tardieu S; Brun-Strang C; Berthaud P; Michallet M; Guilhot F; Rousselot P; Sambuc R
Pharmacoepidemiol Drug Saf; 2005 Aug; 14(8):545-53. PubMed ID: 15534856
[TBL] [Abstract][Full Text] [Related]
35. Occurrence of chronic lymphocytic leukemia in patients with chronic myelogenous leukemia.
Bhattacharyya PK
Indian J Pathol Microbiol; 2013; 56(3):188-9. PubMed ID: 24152491
[TBL] [Abstract][Full Text] [Related]
36. Molecular basis for therapeutic decisions in chronic myeloid leukemia patients after allogeneic bone marrow transplantation.
Román J; Alvarez MA; Torres A
Haematologica; 2000 Oct; 85(10):1072-82. PubMed ID: 11025600
[TBL] [Abstract][Full Text] [Related]
37. Differences in treatment and monitoring of chronic myeloid leukemia with regard to age, but not sex: Results from a population-based study.
Lauseker M; Gerlach R; Worseg W; Haferlach T; Tauscher M; Hasford J; Hoffmann VS
Eur J Haematol; 2019 Oct; 103(4):362-369. PubMed ID: 31309640
[TBL] [Abstract][Full Text] [Related]
38. Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring.
Jabbour E; Kantarjian H
Am J Hematol; 2018 Mar; 93(3):442-459. PubMed ID: 29411417
[TBL] [Abstract][Full Text] [Related]
39. [Predictive value of molecular response after treatment with tyrosine kinase inhibitor for 3 months in patients with chronic myeloid leukemia].
Geng SX; Weng JY; Huang X; Lu ZS; Wu P; Huang LS; Liu L; Du X
Zhonghua Xue Ye Xue Za Zhi; 2013 Jul; 34(7):561-5. PubMed ID: 23906446
[TBL] [Abstract][Full Text] [Related]
40. Bcr/abl recombinant DNA analysis versus karyotype in the diagnosis and therapeutic monitoring of chronic myeloid leukemia.
Ayscue LH; Ross DW; Ozer H; Rao K; Gulley ML; Dent GA
Am J Clin Pathol; 1990 Oct; 94(4):404-9. PubMed ID: 1699406
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
